デジタルバイオマーカー市場 - 世界の産業規模、シェア、動向、機会、予測：コンポーネント別、タイプ別、治療領域別、エンドユーザー別、地域別、競合別、2020年～2030年

デジタルバイオマーカーの世界市場規模は2024年に34億9,000万米ドルとなり、予測期間では2030年までのCAGRが14.88％と目覚ましい成長が予測されています。

デジタルバイオマーカーは、デジタルヘルス技術を利用して、個人が自身の健康状態や治療について積極的に収集する情報をキャプチャします。この情報は、健康状態の説明、影響、予測に使用されます。デジタルバイオマーカーは、睡眠パターン、心拍変動、身体活動、認知機能などの広範なデータを収集することができます。これらのデータは、GPS、加速度計、マイクなどの様々なセンサーを通じて収集され、高度なアルゴリズムと機械学習技術を用いて分析されます。

デジタルバイオマーカーは、事実に基づいた臨床的に価値のあるデータを収集する機会を提供します。必要不可欠な画像処理能力と空間精度の向上に貢献します。デジタルバイオマーカーは、頚動脈導管疾患、胃大動脈瘤、複雑なフリンジ静脈疾患、大動脈解析などのサービスを提供しています。ヘルスケア分野では、デジタルバイオマーカーはビッグデータ発見の一次情報源です。これらは、現在の健康問題を評価するだけでなく、危険なシナリオを予測・評価するのにも役立ちます。これらのデバイスは、埋め込み型、携帯型、消耗品、着用型として利用可能です。病気の早期発見と診断、個別化された治療、生活の質の向上を可能にすることで、デジタルバイオマーカーの応用はヘルスケア分野に変革をもたらします。さらに、傾向やパターンを特定するための豊富な情報を研究者に提供し、新しい治療法や治療法の開発を促進します。さらに、臨床調査において客観的かつ最小限の患者関与でデータを取得することで、信憑性を高めることができ、より正確な医薬品の生産につながります。

主な市場促進要因

がんの有病率の上昇

主な市場課題

高い製品コスト

主な市場動向

デジタルバイオマーカーの使用拡大とウェアラブルデバイスおよびスマートフォンの普及

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のデジタルバイオマーカー市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • コンポーネント別（データ収集ツール、データ統合システム）
  • タイプ別（新規デジタルバイオマーカー、オリジナルデジタルバイオマーカー、承認済みデジタルバイオマーカー）
  • 治療領域別（心血管疾患、睡眠・運動疾患、神経変性疾患、精神疾患、その他）
  • エンドユーザー別（バイオテクノロジーおよび製薬企業、支払者、プロバイダー、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のデジタルバイオマーカー市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のデジタルバイオマーカー市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のデジタルバイオマーカー市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のデジタルバイオマーカー市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのデジタルバイオマーカー市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 世界のデジタルバイオマーカー市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• ActiGraph, LLC
• AliveCor, Inc.
• Altoida AG
• Biogen Inc.
• Fitbit, Inc.
• HumanAPI Inc.
• Pfizer, Inc.
• Sanofi S.A.
• Novartis International AG
• Neurotrack Technologies, Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Digital Biomarkers Market was valued at USD 3.49 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 14.88% through 2030. Digital biomarkers capture information that individuals actively gather about their own well-being or the treatment of a condition using digital health technology. This information is used to explain, influence, and predict health outcomes. Digital biomarkers can collect extensive data, including sleep patterns, heart rate variability, physical activity, and cognitive function. They are collected through various sensors, such as GPS, accelerometers, and microphones, and analyzed using advanced algorithms and machine learning techniques.

Digital biomarkers provide an opportunity to gather factual and clinically valuable data. They contribute to essential imaging capabilities and improved spatial accuracy. Digital biomarkers offer services for carotid conduit disease, stomach aortic aneurysm, complicated fringe vein disease, and aortic analysis. In the healthcare sector, digital biomarkers are the primary source of big data findings. They help evaluate current health issues, as well as predict and assess dangerous scenarios. These devices are available as implanted, portable, consumable, and wearable items. By enabling early disease identification and diagnosis, individualized therapies, and enhancing the quality of life, the application of digital biomarkers can transform the healthcare sector. Additionally, they provide researchers with a wealth of information to identify trends and patterns, facilitating the development of novel cures and treatments. Furthermore, the objective and minimally patient-involved data acquisition in clinical studies can enhance authenticity, leading to the production of more precise medications.

Key Market Drivers

Rise in Prevalence of Cancers

The worldwide pervasiveness of smoking, physical inactivity, and unhealthy food habits significantly influences the incidence of cancer. These habits, when combined, create an environment that promotes the development and progression of cancerous cells within the body. To this end, biomarkers play a crucial role in enabling constant tracking and monitoring of diverse characteristics regarding health and diseases. By measuring specific molecules or genetic alterations, biomarkers provide valuable insights into the underlying mechanisms of cancer development.

The multistage carcinogenesis process involves a series of molecular pathway events that eventually lead to the development of cancer. From the initial genetic mutations to the formation of a tumor, each step in this process contributes to the progression of the disease. Understanding these molecular events is essential for early detection, accurate diagnosis, and effective treatment of cancer. However, the diagnosis, prognosis, and therapy of cancer can be quite complex. Each cancer type differs from other forms based on its unique molecular profile, making it challenging to develop standardized approaches for treatment. This complexity necessitates the need for advanced technologies and innovative solutions to deliver personalized and precise care to patients.

In recent years, the concept of digital biomarkers has emerged as a promising avenue for better analysis and insights into patients' health. These digital biomarkers, collected through various digital health technologies such as wearable devices and mobile applications, provide continuous monitoring of individuals' health parameters. By capturing real-time data on vital signs, physical activity, sleep patterns, and other relevant indicators, digital biomarkers offer a comprehensive view of an individual's health status.

The increasing demand for personalized medicine and the growing adoption of digital health technologies have fueled the growth of the global digital biomarkers market. With the ability to provide objective and quantifiable data, digital biomarkers have opened up numerous opportunities for improving disease management and enhancing patient outcomes. This, in turn, has led to abundant growth in the field, with researchers, healthcare providers, and technology companies actively exploring the potential of digital biomarkers in transforming the future of healthcare.

Key Market Challenges

High Product Cost

The emerging field of digital biomarkers holds great promise for revolutionizing healthcare by providing valuable insights into patients' health and facilitating early disease detection. However, a significant obstacle to the widespread adoption of digital biomarkers is the high product cost associated with their development and implementation. This cost factor poses several challenges to the demand for digital biomarkers in healthcare. The high product cost of digital biomarkers affects their affordability for both healthcare providers and patients. The research, development, and validation processes for digital biomarkers involve substantial investments in technology, data collection, analytics, and regulatory compliance. These costs can translate into expensive licensing fees for healthcare institutions, limiting their ability to integrate these biomarkers into routine patient care.

The financial burden of high-cost digital biomarkers may deter healthcare organizations from investing in the necessary infrastructure and training required for their implementation. Smaller or underfunded healthcare facilities, in particular, may struggle to allocate resources to adopt these advanced technologies, leading to disparities in access to cutting-edge healthcare solutions. Additionally, the high product cost of digital biomarkers may result in higher healthcare expenses for patients. As the cost of implementing and utilizing these biomarkers is passed on to consumers, it could potentially discourage individuals from seeking out and utilizing these technologies, particularly in regions with limited healthcare coverage or insurance.

Key Market Trends

Growing Use of Digital Biomarkers and Penetration of Wearable Devices and Smartphones

The growing utilization of digital biomarkers in diabetes, respiratory diseases, cardiovascular diseases, and sleep disorders serves as a significant driver in the market. The adoption of handheld and wearable digital devices, which constitute a substantial portion of the digital biomarker market, has been facilitated by digital technologies. Health informatics is expanding the global market for digital biomarkers, enabling personalized and cost-effective care. Furthermore, the rapid evolution of telecommunications and IT infrastructure is fueling the demand for digital biomarkers. With increasing investments in healthcare digitalization and smart hospitals by governments and corporations, the global demand for digital biomarkers is expected to witness a boost.

Wearable devices, following Bluetooth headsets, rank as the industry's second-largest innovation. In healthcare, devices such as Google Glass, Apple Watch, Fitbit, MotivRing, and Oculus Rift are widely used. The growing prevalence of wearable devices in healthcare can be attributed to the rising global health awareness, increasing patient population, and the integration of technology into daily life. Numerous apps available on Google Play and iOS platforms monitor sleep, heart rate, and movement. A recent survey revealed that smartphones are utilized in 80% of developed countries and 82% of developing countries.

Key Market Players

• ActiGraph, LLC
• AliveCor, Inc.
• Altoida AG
• Biogen Inc.
• Fitbit, Inc.
• HumanAPI Inc.
• Pfizer, Inc.
• Sanofi S.A.
• Novartis International AG
• Neurotrack Technologies, Inc.

Report Scope:

In this report, the Global Digital Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Digital Biomarkers Market, By Component:

• Data Collection Tools
  • Digital Platforms
  • Mobile Apps
  • Desktop-Based Software
  • Wearable
  • Others
• Data Integration Systems

Digital Biomarkers Market, By Type:

• Novel Digital Biomarkers
• Original Digital Biomarkers
• Approved Digital Biomarkers

Digital Biomarkers Market, By Therapeutic Area:

• Cardiovascular Diseases
• Sleep & Movement Diseases
• Neurodegenerative Disorders
• Psychiatric Disorder
• Others

Digital Biomarkers Market, By End User:

• Biotechnology & Pharmaceutical Companies
• Payers
• Providers
• Others

Digital Biomarkers Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Digital Biomarkers Market.

Available Customizations:

Global Digital Biomarkers market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Digital Biomarkers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Data Collection Tools v/s Data Integration Systems)
    • 5.2.1.1. Data Collection Tools {Digital Platforms, Mobile Apps, Desktop-Based Software, Wearable, Others}
  • 5.2.2. By Type (Novel Digital Biomarkers, Original Digital Biomarkers, Approved Digital Biomarkers)
  • 5.2.3. By Therapeutic Area (Cardiovascular Diseases, Sleep & Movement Diseases, Neurodegenerative Disorders, Psychiatric Disorder, Others)
  • 5.2.4. By End User (Biotechnology & Pharmaceutical Companies, Payers, Providers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Digital Biomarkers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Type
  • 6.2.3. By Therapeutic Area
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Digital Biomarkers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Therapeutic Area
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Digital Biomarkers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Therapeutic Area
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Digital Biomarkers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Therapeutic Area
      • 6.3.3.2.4. By End User

7. Europe Digital Biomarkers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Type
  • 7.2.3. By Therapeutic Area
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Digital Biomarkers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Therapeutic Area
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Digital Biomarkers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Therapeutic Area
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Digital Biomarkers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Therapeutic Area
      • 7.3.3.2.4. By End User
  • 7.3.4. France Digital Biomarkers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Therapeutic Area
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Digital Biomarkers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Therapeutic Area
      • 7.3.5.2.4. By End User

8. Asia-Pacific Digital Biomarkers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Type
  • 8.2.3. By Therapeutic Area
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Digital Biomarkers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Therapeutic Area
      • 8.3.1.2.4. By End User
  • 8.3.2. India Digital Biomarkers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Therapeutic Area
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Digital Biomarkers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Therapeutic Area
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Digital Biomarkers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Therapeutic Area
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Digital Biomarkers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Therapeutic Area
      • 8.3.5.2.4. By End User

9. South America Digital Biomarkers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Type
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Digital Biomarkers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Therapeutic Area
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Digital Biomarkers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Therapeutic Area
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Digital Biomarkers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Therapeutic Area
      • 9.3.3.2.4. By End User

10. Middle East and Africa Digital Biomarkers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Type
  • 10.2.3. By Therapeutic Area
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Digital Biomarkers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Therapeutic Area
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Digital Biomarkers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Therapeutic Area
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Digital Biomarkers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Therapeutic Area
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Digital Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. ActiGraph, LLC
  • 15.1.1. Business Overview
  • 15.1.2. Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AliveCor, Inc.
• 15.3. Altoida AG
• 15.4. Biogen Inc.
• 15.5. Fitbit, Inc.
• 15.6. HumanAPI Inc.
• 15.7. Pfizer, Inc.
• 15.8. Sanofi S.A.
• 15.9. Novartis International AG
• 15.10. Neurotrack Technologies, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer